Tag: InspireMD
InspireMD and NAMSA to partner on CGUARDIANS II pivotal clinical trial
InspireMD and North American Science Associates (NAMSA) today announced that, pursuant to a previously announced strategic outsourcing partnership, the companies are working together to conduct...
First patient enrolled in InspireMD’s CGUARDIANS II pivotal study
InspireMD today announced that the first patient has been enrolled in the company’s CGUARDIANS II clinical trial evaluating its CGuard Prime carotid stent system in...
InspireMD receives IDE approval from US FDA for CGUARDIANS II pivotal...
InspireMD has announced US Food and Drug Administration (FDA) approval of the company’s investigational device exemption (IDE) application to initiate the CGUARDIANS II pivotal...
InspireMD congratulates CREST-2 investigators on completion of trial enrolment
InspireMD today congratulated the lead investigators on the completion of enrolment in the CREST-2 clinical trials.
The CGuard embolic prevention stent system (EPS), utilising...
LINC 2024: C-GUARDIANS data represent lowest event rates in published trials...
New data from the C-GUARDIANS pivotal investigational device exemption (IDE) trial support consideration of carotid artery stenting (CAS) with the CGuard embolic prevention stent...
InspireMD receives CE-mark recertification under new EU regulatory framework
InspireMD announced today that it has received CE-mark recertification under the European Union’s (EU) new Medical Device Regulation (MDR) regulatory framework for its CGuard...
InspireMD presents positive 30-day follow-up results from C-GUARDIANS clinical trial
InspireMD recently presented 30-day results from the C-GUARDIANS US investigational device exemption (IDE) clinical trial evaluating its CGuard embolic prevention stent (EPS) system for...
InspireMD announces completed enrolment in C-Guardians US IDE trial
InspireMD today announced that it has completed enrolment of its ongoing C-Guardians US Investigational Device Exemption (IDE) clinical trial, designed to support potential US...
InspireMD announces the inclusion of its CGuard carotid stent in CREST-2...
InspireMD has announced that its CGuard embolic prevention stent system (EPS) will be included as a device option for stenting in CREST-2 (Carotid revascularisation...
InspireMD report “superior clinical outcomes” for next-generation mesh-covered stents
InspireMD has released the results of a meta-analysis of four clinical studies involving dual-layered and mesh-covered stents, including the company’s MicroNet-covered stent, the CGuard...
Expanded two-year follow-up results from the PARADIGM clinical study using CGuard...
Piotr Musiałek, from the Department of Cardiac and Vascular Diseases, John Paul II Hospital, Kraków, Poland, presented the expanded 24-month follow-up results from the...
